Contribution of bradykinin to the cardioprotective effects of ACE inhibitors

被引：17

作者：

Murphey, L

Vaughan, D

Brown, N

机构：

[1] Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Sch Med, Nashville, TN USA

[2] Vanderbilt Univ, Div Clin Pharmacol, Dept Pharmacol, Sch Med, Nashville, TN USA

[3] Vanderbilt Univ, Div Cardiovasc Med, Dept Med, Sch Med, Nashville, TN USA

[4] Vanderbilt Univ, Div Cardiovasc Med, Dept Pharmacol, Sch Med, Nashville, TN USA

[5] Vet Affairs Med Ctr, Nashville, TN 37212 USA

来源：

EUROPEAN HEART JOURNAL SUPPLEMENTS | 2003年 / 5卷 / 0A期

关键词：

ACE inhibitors; ramipril; bradykinin; endothelial dysfunction; kallikrein-kinin system; renin-angiotensin system;

D O I：

10.1016/S1520-765X(03)90062-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bradykinin, through its B-2 receptor, stimulates endothelial release of a number of vasodilators, such as nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). Angiotensin-converting enzyme (ACE) inhibitors enhance the effects of local bradykinin by decreasing its degradation and by increasing B-2 receptor sensitivity. Clinical and experimental studies demonstrate that blockade of the B-2 receptor attenuates the antihypertensive, antihypertrophic, and antiatherosclerotic effects of ACE inhibitors. Thus, the evidence strongly supports a role for bradykinin in mediating the cardiovascular benefits of ACE inhibitors. (C) 2003 The European Society of Cardiology.

引用

页码：A37 / A41

页数：5

共 49 条

[1] Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure [J].